C-RAD AB with its three fully owned subsidiaries and three international sales companies are all active in the field of radiation therapy. The China Food and Drug Administration has approved the Sentinel System.
The CFDA approval is the prerequisite for medical device vendors to take part in most public procurement processes for governmental funded hospitals. The majority of cancer centers in China are either regional financed or military hospitals. The approval includes the functionality of patient positioning and motion monitoring.
The C-RAD Sentinel system is a laser scanning system to be used for precise and fast positioning of the patient before the radiation therapy treatment. During the treatment the system will be used for motion control. Interfaces to the major linear accelerators vendors are available for automatic couch control.
The approval for C-RAD’s newly developed Catalyst System has been started in 2013.
Tim Thurn, CEO of C-RAD AB:
“I am glad to announce the finalization of the approval of the C-RAD Sentinel System in China. China is one of the fastest growing markets within radiation therapy worldwide. Our direct sales organization, our distributor and partners have already started to promote the system to their customers.”
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 28 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.
For more information on C-RAD, please visit www.c-rad.com.
For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail email@example.com